XOMA
XOMA Corp

7,348
Loading...
Loading...
News
all
press releases
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
The firm stated it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation.
Stocktwits·2d ago
News Placeholder
More News
News Placeholder
Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·13d ago
News Placeholder
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·29d ago
News Placeholder
Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·1mo ago
News Placeholder
Mural Oncology To Be Acquired By XOMA Royalty
The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders.
Stocktwits·1mo ago
News Placeholder
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
News Placeholder
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
XOMA Royalty (XOMA) delivered earnings and revenue surprises of +500.00% and +39.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps
XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right.
Stocktwits·3mo ago

Latest XOMA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.